Invited speaker:
Prof. Thierry André, MD
Principal Investigator, Medical Oncologist
Sorbonne Université and Saint Antoine Hospital, Paris
Moderator:
Assoc. Prof. Jakob Eberhard, MD
Principal Investigator, Sr Consultant in Oncology
Skåne University Hospital, Lund
Immunotherapies approved in Europe for patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) colorectal cancer at the time this webinar was recorded (April 2nd 2025):
Nivolumab and Ipilimumab
Nivolumab in combination with ipilimumab is indicated for the treatment of adult patients with dMMR or MSI-H CRC in the following settings:
- First-line treatment of unresectable or metastatic CRC;
- Treatment of metastatic CRC after prior fluoropyrimidine-based combination chemotherapy
Pembrolizumab
Pembrolizumab as monotherapy is indicated for adults with MSI-H or dMMR CRC in the following settings:
- First-line treatment of metastatic CRC;
- Treatment of unresectable or metastatic CRC after previous fluoropyrimidine-based combination therapy.
APRIL 2025 ONC-NOR-2500005
